Lilly reports durable first‑line activity of olomorasib in KRAS G12C‑mutant lung cancer at ESMO
Eli Lilly presented data from a poster and a rapid oral presentation at the 2026 ESMO Congress showing its investigational KRAS G12C inhibitor olomorasib combined with pembrolizumab, with or without chemotherapy, in first‑line non‑small cell lung cancer. In the chemo‑immunotherapy cohort, the median duration of response was 14.5 months and the investigator‑assessed overall response rate was 62%. Lilly said the first randomized Phase 3 data from the SUNRAY‑01 study are expected in the first half of 2027.
Why it matters
The company notes that the results suggest a potentially effective first‑line option for a patient population with high unmet need, which could drive future sales if the Phase 3 trial confirms efficacy. The upcoming Phase 3 readout in early 2027 will be a key catalyst for the stock.
Key facts
- 1Median duration of response was 14.5 months in the olomorasib plus chemo‑immunotherapy arm. prnewswire.com
- 2Investigator‑assessed overall response rate was 62% (48/77 patients) in the same arm. prnewswire.com
- 3Median follow‑up for the chemo‑immunotherapy cohort was 18.7 months. prnewswire.com
- 4In the olomorasib plus pembrolizumab without chemotherapy arm, 85 patients were evaluated and 64% had PD‑L1 expression ≥50%. prnewswire.com
- 5Lilly expects first randomized Phase 3 data from SUNRAY‑01 in the first half of 2027. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.